Assembly Biosciences (ASMB) 8-K Ventrus Biosciences Receives Date for Type B pre-NDA Meeting with FDA for DOLIZEM (Diltiazem Hydrochloride Cream) in Anal Fissures

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 4, 2014

VENTRUS BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-35005	20-8729264
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer ID Number)

99 Hudson Street, 5^th Floor, New York, New York                                     10013

(Address of principal executive offices)                                                     (Zip Code)

Registrant’s telephone number, including area code (646) 706-5208

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On April 4, 2014, Ventrus Biosciences, Inc. issued a press release announcing that the U.S. Food and Drug Administration has scheduled a Type B pre-NDA meeting on June 19, 2014 at which the company will seek guidance on its planned new drug application for DOLIZEM (diltiazem hydrochloride cream) in anal fissures.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Press release dated April 4, 2014.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	VENTRUS BIOSCIENCES, INC.
Date:  April 4, 2014	/s/ David J. Barrett
	David J. Barrett, Chief Financial Officer